Jefferies Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Predicting Strong Kyprolis Launch

Jefferies reiterates a 'Buy' on Onyx Pharmaceuticals (NASDAQ: ONXX) price target of $101.00.

Analyst, Biren Amin, said, "With Kyprolis recently launched, we conducted a proprietary MM survey to address uncertainty typical around a biotech drug launch. Based on survey results there could be significant upside to our/St current ests and valuation. Our survey results predict a robust launch with stronger-than-expected 2013-14 uptake across key 2nd-line/beyond settings."

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $67.80 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• New Street Research Upgrades Micron Technology (MU) to Buy
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)